Want to see UNCY full AI Analyst Report?
Unicycive Therapeutics (UNCY) AI Stock Analysis
Top Page
Unicycive Therapeutics
(NASDAQ:UNCY)
The score is primarily held down by weak financial performance (zero revenue, sizable losses, and ongoing cash burn), which outweighs balance-sheet improvements. Technicals also detract due to a clear downtrend despite oversold readings. Corporate events are mixed, with a constructive NDA resubmission offset by litigation risk, while valuation metrics offer limited support given continued unprofitability.
Unicycive Therapeutics (UNCY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $102.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 896.53K
- Price to Earnings (P/E)
- -2.2
- Beta (1Y)
- 1.60
- Revenue Growth
- ―
- EPS Growth
- 43.63%
- Country
- US
- Employees
- 21
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Unicycive Therapeutics Business Overview & Revenue Model
Company Description
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients,...
Unicycive Therapeutics Financial Statement Overview
Summary
Financials are constrained by an early-stage, loss-making profile: TTM revenue is $0 with a large net loss (~$35.2M) and continued cash burn (TTM operating cash flow and free cash flow both about -$27.8M). The main offset is an improved and lightly levered balance sheet (only ~$0.7M debt vs ~$53.3M equity), but ongoing losses keep dilution/financing risk elevated.
Income Statement
18Very NegativeBalance Sheet
56NeutralCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 675.00K | 951.00K | 0 |
| Gross Profit | -211.00K | -572.00K | 0 | 675.00K | 951.00K | 0 |
| EBITDA | -34.52M | -25.91M | -36.23M | -30.18M | -17.89M | -9.38M |
| Net Income | -35.22M | -26.55M | -36.73M | -30.54M | -18.06M | -10.02M |
Balance Sheet | ||||||
| Total Assets | 72.03M | 49.13M | 31.67M | 14.19M | 2.82M | 18.74M |
| Cash, Cash Equivalents and Short-Term Investments | 61.42M | 41.27M | 26.14M | 9.70M | 455.00K | 16.58M |
| Total Debt | 671.00K | 199.00K | 773.00K | 811.00K | 201.00K | 335.00K |
| Total Liabilities | 18.76M | 18.94M | 24.24M | 18.00M | 3.28M | 2.26M |
| Stockholders Equity | 53.27M | 30.20M | 7.43M | -3.81M | -466.00K | 16.48M |
Cash Flow | ||||||
| Free Cash Flow | -27.85M | -31.34M | -28.65M | -18.30M | -15.65M | -5.80M |
| Operating Cash Flow | -27.84M | -31.32M | -28.57M | -18.28M | -15.65M | -5.77M |
| Investing Cash Flow | -17.25M | -12.10M | -72.00K | -12.00K | -2,000 | -29.00K |
| Financing Cash Flow | 66.95M | 46.47M | 45.09M | 27.54M | -471.00K | 22.38M |
Unicycive Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNCY, the sentiment is Negative. The current price of 3.74 is below the 20-day moving average (MA) of 3.84, below the 50-day MA of 4.54, and below the 200-day MA of 6.10, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 40.46 is Neutral, neither overbought nor oversold. The STOCH value of 47.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UNCY.
Unicycive Therapeutics Risk Analysis
Unicycive Therapeutics disclosed 56 risk factors in its most recent earnings report. Unicycive Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskUnicycive Therapeutics Peers Comparison
Overall Rating
FBIO66.6Neutral
CVM49Neutral
EQ46Neutral- UNCY45Neutral
CBUS44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FBIO | 67Neutral | $64.03M | 0.59 | 103.52% | ― | 15.46% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CVM | 49Neutral | $24.27M | -0.53 | -202.14% | ― | ― | 73.69% |
| EQ | 46Neutral | $86.87M | -5.34 | -41.15% | ― | -100.00% | 64.23% |
| UNCY | 45Neutral | $104.18M | -2.23 | -88.81% | ― | ― | 43.63% |
| CBUS | 44Neutral | $98.59M | -0.78 | -320.60% | ― | -10.30% | 84.17% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| UNCY | Unicycive Therapeutics, Inc. | 3.74 | -0.70 | -15.77% | |
| CVM | Cel-sci | 1.38 | -5.71 | -80.54% | |
| FBIO | Fortress Biotech Inc | 1.92 | -0.52 | -21.31% | |
| CBUS | Cibus, Inc. | 1.29 | -0.15 | -10.42% | |
| EQ | Equillium | 1.37 | -0.18 | -11.61% |
Unicycive Therapeutics Corporate Events
Unicycive Resubmits NDA for Kidney Disease Treatment
PositiveOn September 29, 2026, Unicycive Therapeutics announced it had resubmitted its New Drug Application for oxylanthanum carbonate, an oral phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis. The resubmission follows pr...
Unicycive Faces New Securities Class Action Over NDA Disclosures
NegativeOn September 3, 2026, a securities class action lawsuit was filed in the United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. and certain executives, alleging violations of federal securities laws...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026